Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda

Trans R Soc Trop Med Hyg. 2016 Aug;110(8):495-7. doi: 10.1093/trstmh/trw055. Epub 2016 Sep 12.

Abstract

Background: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at 24 weeks in patients undergoing HCV therapy in Kigali, Rwanda.

Methods: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014.

Results and conclusions: There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes.

Keywords: Hepatitis C virus; Interferon; Ribavirin; Rwanda; sub-Saharan Africa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus / drug effects*
  • Hepacivirus / genetics
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology
  • Hospitals
  • Humans
  • Interferons / pharmacology
  • Interferons / therapeutic use*
  • Middle Aged
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use*
  • Rwanda
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Ribavirin
  • Interferons